ASCENTAGE-B (06855) Achieves high growth with dual-engine drive, with Naike's sales increasing by 81% year-on-year.

On March 26, the leading innovative drug company Yasheng Medicine (NASDAQ: AAPG; HKEX: 6855) released its full-year performance for 2025. During the reporting period, the company achieved a total revenue of 574 million RMB, with strong commercialization growth. As the company's first commercialized product, Nalinike (Oribatini) saw a significant increase in sales after its inclusion in medical insurance in 2025, reaching 435 million RMB, a year-on-year increase of 81%. The company's second product, China's first domestically produced original Bcl-2 inhibitor, Lixintuo (Lisatoclax), achieved rapid sales growth after its approval in July 2025, with sales of 70.58 million RMB in the five months leading up to the end of the reporting period. The company's cash flow continued to improve, with ample funds, totaling approximately 2.47 billion RMB at the end of the reporting period. The performance growth was driven by the efficient operation of the two core products already on the market. On a global clinical development level, the company also achieved milestone breakthroughs. Nalinike's global Phase III registration study for first-line treatment of Ph+ ALL (POLARIS-1) and Lixintuo's global Phase III registration study for the treatment of high-risk MDS (GLORA-4) both received approval from the US FDA and EMA in 2025. The company currently has multiple Phase III registration studies progressing globally, four of which have received approval from the US FDA and EMA. To support the rapid development of its business, Yasheng Medicine's commercialization team rapidly expanded, surpassing 270 by the end of 2025, covering over 1,500 hospitals nationwide, with plans for further expansion in 2026. In January 2025, the company successfully listed on NASDAQ, becoming the first biopharmaceutical company to have a dual primary listing in both Hong Kong and the US. Dr. Yang Dajun, Chairman and CEO of Yasheng Medicine, stated, "2025 was a pivotal year for Yasheng Medicine's global expansion. We achieved breakthroughs in product commercialization, global clinical development, pipeline innovation, and capital markets across multiple dimensions. Our commercialization strategy is steadily progressing, with a 'dual-engine' layout centered around Nalinike and Lixintuo successfully established. In 2026, we will continue to focus on meeting the unmet needs of patients, accelerate global clinical development of core products, and strive to become a global leader in the field of innovative blood cancer."